Search
Guanisoquin
go.drugbank.com/drugs/DB19760ExperimentalGuanisoquin is a small molecule drug. Guanisoquin has a monoisotopic molecular weight of 253.02 Da.
Cipralisant
go.drugbank.com/drugs/DB19761ExperimentalCipralisant is a small molecule drug. The usage of the INN stem '-isant' in the name indicates that Cipralisant is a histamine H3 receptor antagonist. … Cipralisant has a monoisotopic molecular weight of 216.16 Da.
Categories: Heterocyclic Compounds, 1-RingCopanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalCopanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDESamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Salts: Samidorphan L-malateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational>A</sub>R and 0.8 nM for AT<sub>1</sub>R). … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub
Categories: Angiotensin 2 Receptor Blocker, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)Nafamostat
go.drugbank.com/drugs/DB12598InvestigationalNafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. … The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.
Synonyms: p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidineOctenidine
go.drugbank.com/drugs/DB12624InvestigationalOctenidine is under investigation in clinical trial NCT02697162 (Antiseptic-coated Intermittent Urinary Catheter).
Mixtures: Linola sept 1 mg/g + 10 mg/g Wund-Gel, Linola sept 1 mg/g + 20 mg/g Wund-Spray zur Anwendung auf der Haut, LösungCategories: Heterocyclic Compounds, 1-RingCC-115
go.drugbank.com/drugs/DB12740InvestigationalCC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.
Categories: Heterocyclic Compounds, 1-RingLometrexol
go.drugbank.com/drugs/DB12769InvestigationalLometrexol has been used in trials studying the treatment of Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, and Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Heterocyclic Compounds, 2-RingPegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalFood and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients with phenylketonuria (PKU). … /L to 3690 µmol/L [A33286].